Torsten Dahlén

Publications
CV
Public outreach and news

Articles

Article: THE LANCET: DIGITAL HEALTH. 2024;6(2):e105-e113
Using routine health-care data to search for unknown transfusion-transmitted disease: a nationwide, agnostic retrospective cohort study
Dahlen T; Zhao J; Busch MP; Edgren G
Article: JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (JAMA). 2023;330(10):941-950
Intracerebral Hemorrhage Among Blood Donors and Their Transfusion Recipients
Zhao J; Rostgaard K; Lauwers E; Dahlen T; Ostrowski SR; Erikstrup C; Pedersen OB; de Strooper B; Lemmens R; Hjalgrim H; Edgren G
Article: JOURNAL OF INTERNAL MEDICINE. 2023;293(3):398-402
A population-based, retrospective cohort study of the association between ABO blood group and risk of COVID-19
Dahlen T; Li H; Nyberg F; Edgren G
Article: JOURNAL OF THE AMERICAN HEART ASSOCIATION. 2022;11(11):e024091
Neutrophil-to-Lymphocyte Ratios in Patients Undergoing Aortic Valve Replacement: The PARTNER Trials and Registries
Shahim B; Redfors B; Lindman BR; Chen S; Dahlen T; Nazif T; Kapadia S; Gertz ZM; Crowley AC; Li D; Thourani VH; Kodali SK; Zajarias A; Babaliaros VC; Guyton RA; Elmariah S; Herrmann HC; Cohen DJ; Mack MJ; Smith CR; Leon MB; George I
Article: AMERICAN JOURNAL OF HEMATOLOGY. 2022;97(4):421-430
Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Follow-up of patients diagnosed 2002-2017 in a complete coverage and nationwide agnostic register study
Dahlen T; Edgren G; Ljungman P; Flygt H; Richter J; Olsson-Stromberg U; Wadenvik H; Dreimane A; Myhr-Eriksson K; Zhao J; Sjalander A; Hoglund M; Stenke L
Article: JOURNAL OF INTERNAL MEDICINE. 2022;291(1):95-100
The frequency of misattributed paternity in Sweden is low and decreasing: A nationwide cohort study
Dahlen T; Zhao J; Magnusson PKE; Pawitan Y; Lavrod J; Edgren G
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2021;193(5):915-921
Successful tyrosine kinase inhibitor discontinuation outside clinical trials - data from the population-based Swedish chronic myeloid leukaemia registry
Flygt H; Sandin F; Dahlen T; Dremaine A; Lubking A; Markevarn B; Myhr-Eriksson K; Olsson K; Olsson-Stromberg U; Sjalander A; Soderlund S; Wennstrom L; Wadenvik H; Stenke L; Hoglund M; Richter J
Article: VOX SANGUINIS. 2021;116(5):581-590
Costs associated with transfusion therapy in patients with myelodysplastic syndromes in Sweden: a nationwide retrospective cohort study
Zhao J; Dahlen T; Edgren G
Article: ELIFE. 2021;10:e65658
An agnostic study of associations between ABO and RhD blood group and phenome-wide disease risk
Dahlen T; Clements M; Zhao J; Olsson ML; Edgren G
Article: TRANSFUSION. 2020;60(11):2591-2596
Risk of hematological malignancy in blood donors: A nationwide cohort study
Zhao J; Dahlen T; Brynolf A; Edgren G
Article: PLOS COMPUTATIONAL BIOLOGY. 2020;16(6):e1007927
Measurable health effects associated with the daylight saving time shift
Zhang H; Dahlen T; Khan A; Edgren G; Rzhetsky A
Article: NATURE COMMUNICATIONS. 2019;10(1):5508
Estimating heritability and genetic correlations from large health datasets in the absence of genetic data
Jia G; Li Y; Zhang H; Chattopadhyay I; Jensen AB; Blair DR; Davis L; Robinson PN; Dahlen T; Brunak S; Benson M; Edgren G; Cox NJ; Gao X; Rzhetsky A
Article: APPLIED HEALTH ECONOMICS AND HEALTH POLICY. 2019;17(4):555-567
Cost Effectiveness of the Third-Generation Tyrosine Kinase Inhibitor (TKI) Ponatinib, vs. Second-Generation TKIs or Stem Cell Transplant, as Third-Line Treatment for Chronic-Phase Chronic Myeloid Leukemia
Hirt C; Iannazzo S; Chiroli S; McGarry LJ; le Coutre P; Stenke L; Dahlen T; Lipton JH
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2017;98(1):57-66
Advanced phase chronic myeloid leukaemia (CML) in the tyrosine kinase inhibitor era - a report from the Swedish CML register
Soderlund S; Dahlen T; Sandin F; Olsson-Stromberg U; Creignou M; Dreimane A; Lubking A; Markevarn B; Sjalander A; Wadenvik H; Stenke L; Richter J; Hoglund M
Article: ANNALS OF INTERNAL MEDICINE. 2016;165(3):161-166
Cardiovascular Events Associated With Use of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia A Population-Based Cohort Study
Dahlen T; Edgren G; Lambe M; Hoglund M; Bjorkholm M; Sandin F; Sjalander A; Richter J; Olsson-Stromberg U; Ohm L; Back M; Stenke L
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2016;96(2):175-180
Decreased invasive fungal disease but no impact on overall survival by posaconazole compared to fluconazole prophylaxis: a retrospective cohort study in patients receiving induction therapy for acute myeloid leukaemia/myelodysplastic syndromes
Dahlen T; Kalin M; Cederlund K; Nordlander A; Bjorkholm M; Ljungman P; Blennow O

All other publications

Letter: LEUKEMIA. 2023;37(5):1156-1159
The impact of Covid-19 in patients with chronic myeloid leukemia-a nationwide population-based study
Dahlen T; Flygt H; Lubking A; Olsson-Stromberg U; Wennstrom L; Dreimane A; Sjalander A; Leach S; Gisslen M; Li H; Hoglund M; Stenke L; Nyberg F
Thesis / dissertation: 2023
Agnostic studies in epidemiology
Dahlén, Torsten

Employments

Affiliated to Research, Department of Medicine, Karolinska Institutet, 2024-2024

Degrees and Education

Degree Of Doctor Of Philosophy, Department of Medicine, Solna, Karolinska Institutet, 2023
University Medical Degree, Karolinska Institutet, 2012

Supervisor

Enoch Chen, Extrapolating survival with applications in health technology assessment, 2021

Articles

All other publications

Employments

Degrees and Education

Supervisor

News from KI

Events from KI